In the pilot phase, no clinical responses were observed
in 18 patients unselected TILs.
However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%).
Pembrolizumab
was added, and 8 objective responses were
seen in 34 patients (23.5%)